Clinical trial
Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian…
NCT00327171 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00327171 |
|---|---|
| Title | Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer |
| Official title | A Multicenter, Randomized, Double-blind, Parallel-arm, Two-stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum-resistant and topotecan-and/or Liposomal Doxorubicin-resistant Advanced Ovarian Cancer |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Regeneron Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Cancer of the Ovary |
| Intervention type | Drug |
| Interventions | Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) |
| Enrollment | 218 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Mar 1, 2010 |
| First posted | May 18, 2006 |
| Last update posted | Jun 7, 2016 |
| Countries | Australia, Canada, France, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: